Clinical trial
A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With…
NCT00485836 · Genentech, Inc., Industry · Completed
Key facts
| NCT number | NCT00485836 |
|---|---|
| Title | A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion (CRUISE) |
| Official title | A Phase III, Multicenter, Randomized, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab Injection Compared With Sham in Subjects With Macular Edema Secondary to Central Retinal Vein Occlusion |
| Acronym | CRUISE |
| Lead sponsor | Genentech, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Macular Edema, Retinal Vein Occlusion |
| Intervention type | Drug |
| Interventions | Sham injection, Ranibizumab injection 0.3 mg, Ranibizumab injection 0.5 mg |
| Enrollment | 392 |
| Start date | Jul 1, 2007 |
| Primary completion | Jun 1, 2009 |
| Completion | Dec 1, 2009 |
| First posted | Jun 13, 2007 |
| Last update posted | Jul 28, 2017 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: